| 组蛋白去乙酰化酶抑制剂在肾脏疾病中的研究进展* |
| |
| 引用本文： | 杨晓鹏,田莎莎,郭珲.组蛋白去乙酰化酶抑制剂在肾脏疾病中的研究进展*[J].中国现代医学杂志,2021,31(2):43-47. |
| |
| 作者姓名： | 杨晓鹏 田莎莎 郭珲 |
| |
| 作者单位： | （1.山西医科大学第二临床医学院，山西 太原 030001；2.山西医科大学第二医院 肾内科，
山西 太原 030001） |
| |
| 基金项目： | 山西省回国留学人员科研项目（No：2017-116） |
| |
| 摘 要： | 组蛋白去乙酰化酶（HDAC） 可以诱导组蛋白和非组蛋白去乙酰化，在基因表达的表观遗传调节
方面发挥重要作用。越来越多的证据表明HDAC参与各种肾脏疾病的发生、发展，强调抑制其活性可作为肾
脏疾病的一种重要治疗策略。该文综述了组蛋白去乙酰化酶抑制剂在肾小管间质纤维化、糖尿病肾病、多囊肾
病、急性肾损伤和狼疮性肾炎等肾脏疾病中的作用机制，以期为各种肾脏疾病的临床诊疗提供新靶点。
|
| 关 键 词： | 组蛋白 组蛋白去乙酰化酶 组蛋白去乙酰化酶抑制剂 肾脏疾病 |
| 收稿时间： | 2020/7/25 0:00:00 |
Research Advancementsprogress onf the role of histone deacetylase
inhibitors in kidney diseases* |
| |
| Xiao-peng Yang,Sha-sha Tian,Hui Guo.Research Advancementsprogress onf the role of histone deacetylase
inhibitors in kidney diseases*[J].China Journal of Modern Medicine,2021,31(2):43-47. |
| |
| Authors: | Xiao-peng Yang Sha-sha Tian Hui Guo |
| |
| Institution: | (1. The Second College of Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi 030001, China;
2. Department of Nephrology, the Second Clinical Medical College, Hospital of Shanxi Medical
University, Taiyuan, Shanxi 030001, China) |
| |
| Abstract: | Histone deacetylase (HDAC) can induce deacetylation of both histone and non-histone proteins,
and plays an important role in epigenetic regulation of gene expression. Increasing evidence has shown the
involvement of HDAC in the development and progression of various renal diseases, highlighting the inhibition of
HDAC as a promising therapeutic strategy to kidney diseases. This review focuses on the potential therapeutic
effects and relevant mechanisms of HDAC inhibitors in kidney diseases including tubulointerstitial fibrosis, diabetic
nephropathy, polycystic kidney disease, acute kidney injury and lupus nephritis, in order to provide new targets for
clinical diagnosis and treatment of various renal diseases. |
| |
| Keywords: | histone histone deacetylase histone deacetylase inhibitor kidney diseases |
|
| 点击此处可从《中国现代医学杂志》浏览原始摘要信息 |
| 点击此处可从《中国现代医学杂志》下载免费的PDF全文 |
